Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) EBIT Margin (2016 - 2025)

Celldex Therapeutics has reported EBIT Margin over the past 16 years, most recently at 72027.27% for Q4 2025.

  • Quarterly results put EBIT Margin at 72027.27% for Q4 2025, down 6725902.0% from a year ago — trailing twelve months through Dec 2025 was 18587.71% (down 1580882.0% YoY), and the annual figure for FY2025 was 18599.81%, down 1582092.0%.
  • EBIT Margin for Q4 2025 was 72027.27% at Celldex Therapeutics, down from 8747.53% in the prior quarter.
  • Over the last five years, EBIT Margin for CLDX hit a ceiling of 10792.81% in Q4 2021 and a floor of 72027.27% in Q4 2025.
  • Median EBIT Margin over the past 5 years was 4768.26% (2024), compared with a mean of 10187.87%.
  • Peak annual rise in EBIT Margin hit 1700357bps in 2025, while the deepest fall reached -6725902bps in 2025.
  • Celldex Therapeutics' EBIT Margin stood at 10792.81% in 2021, then tumbled by -116bps to 1728.77% in 2022, then surged by 33bps to 1152.92% in 2023, then plummeted by -314bps to 4768.26% in 2024, then plummeted by -1411bps to 72027.27% in 2025.
  • The last three reported values for EBIT Margin were 72027.27% (Q4 2025), 8747.53% (Q2 2025), and 9027.19% (Q1 2025) per Business Quant data.